Triple Mutation Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719S), 20 (T790M) and 21 (L858R) in a Male Patient with Lung Adenocarcinoma: A Case Report
Downloads
Background: Lung cancer is one of the deadliest cancers in the world. The percentage of non small cell lung cancer (NSCLC) is about 80% of the incidence of lung cancer. The type of NSCLC, adenocarcinoma, is usually found in the presence of epidermal growth factor receptor (EGFR) mutations.
Case. A male patient aged 70 years, an active smoker, works as a farmer. He has complained of shortness of breath, and chest pain for three months. There was no family history of suffering from malignancy. The cytology result of the right pleural fluid indicated adenocarcinoma. He was diagnosed with pulmonary adenocarcinoma (D) stage IV positive mutation of EGFR exon 18 (G719S), 20 (T790M) and 21 (L858R) carnofsky score 70. He could survive for more than 11 months with the treatment of EGFR TKI, and received a good therapeutic response. Initially, for the first six months it was such a progressive disease, and for the next eleven months it became stable.
Conclusion: In addition to the exon mutations found in this case, the cells in the tumor will continue to grow and develop into new mutants that are immune such drugs and rapidly split themselves into new, different forms. The therapy for complex mutations is still being developed. EGFR TKI therapy in this patient had a relatively good response. Further understanding of the molecular biology of lung cancer is seriously required.
Midha A, Dearden S and Mccormack R. EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (Mutmapii). American Journal of Cancer Research. 2015; 5: 2892-911.
Society AC. Non-Small Cell Lung Cancer. Atlanta: American Cancer Society, 2016.
Ries L, Eisner M and Kosary C. International Agency for Research on Cancer.
Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medicine. 2004; 350: 2129-39.
Pao W, Miller V, Zakowski M, et al. EGF Receptor Gene Mutations are Common in Lung Cancers from "Never Smokers” and are Associated with Sensitivity of Tumors to Gefitinib And Erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 13306-11.
Huang SF, Liu HP, Li LH, et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non-Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2004; 10: 8195-203.
Tahara E, Yasui W, Ito H and Harris CC. Recent Progress in Carcinogenesis, Progression and Therapy of Lung Cancer: The 19th Hiroshima Cancer Seminar: The 3rd Three Universities' Consortium International Symposium, November 2009. Japanese Journal of Clinical Oncology. 2010; 40: 702-8.
Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10 117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2014; 25: 126-31.
Hata A, Yoshioka H, Fujita S, et al. Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2010; 5: 1524-8.
Griffiths AJ, Miller JH, Suzuki DT, Lewontin RC and Gelbart WM. An Introduction to Genetic Analysis. New York: W. H. Freeman, 2000.
Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA Somatic Mutations in Lung Cancer: A Comprehensive Mutation Profiling from 5125 Chinese Cohorts. British Journal of Cancer. 2014; 110: 2812-20.
Lammers PE, Lovly CM and Horn L. A Patient with Metastatic Lung Adenocarcinoma Harboring Concurrent EGFR L858R, EGFR Germline T790M, and PIK3CA Mutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014; 12: 6-11; Quiz
Siegelin MD and Borczuk AC. Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Laboratory Investigation; A Journal of Technical Methods and Pathology. 2014; 94: 129-37.
Ettinger DS, Aisner DL, Wood DE, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2018; 16: 807-21.
Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 2013; 8: 45-51.
Tan WW. Non-Small Cell Lung Cancer (NSCLC). 2016.
Widyaningrum RRE, Heriyanto DS and Anwar SL. Hubungan Usia dengan Mutasi Gen Epidermal Growth Factor Receptor Ekson 18 dan 19 pada Pasien dengan Kanker Paru Jenis Adenokarsinoma. Yogyakarta: Universitas Gadjah Mada, 2016.
Lou Y, Pecot CV, Tran HT, Et Al. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma. Clinical Lung Cancer. 2016; 17: E5-11.
Indonesia PO. Basic Science Of Oncology. Jakarta: Fakultas Kedokteran Universitas Indonesia, 2010.
De Biase D, Visani M, Malapelle U, et al. Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). Plos One. 2013; 8: E83607.
Kanker KNP. Panduan Nasional Penanggulangan Kanker Paru. Jakarta: Kementerian Kesehatan Republik Indonesia, 2015.
Ranson M. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. British Journal of Cancer. 2004; 90: 2250-5.
Zhang Y, Sheng J, Kang S, et al. Patients with Exon 19 Deletion were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation After First-Line EGFR-TKIS for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. Plos One. 2014; 9: E107161.
Zhang H. Osimertinib Making a Breakthrough in Lung Cancer Targeted Therapy. Onco Targets Ther. 2016; 9: 5489-93.
Normanno N, Maiello MR and De Luca A. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIS): Simple Drugs with A Complex Mechanism of Action? Journal Of Cellular Physiology. 2003; 194: 13-9.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (